Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors

被引：16
作者：
Stine, Kimo C. [1 ]
Shrum, Dixie [1 ]
Becton, David L. [1 ]
机构：
[1] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat Hematol Oncol, Little Rock, AR 72202 USA
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2007年 / 29卷 / 04期
关键词：
hemophilia; inhibitors; surgery; FEIBA; RECOMBINANT FACTOR-VIIA; PROTHROMBIN COMPLEX CONCENTRATE; FACTOR-IX INHIBITORS; ORTHOPEDIC-SURGERY; BYPASS ACTIVITY; EFFICACY; THERAPY; SAFETY; THROMBOSIS; MANAGEMENT;
D O I：
10.1097/MPH.0b013e318041f101
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Achieving hemostasis in patients with hemophilia A or B is complicated by the presence of inhibitors and is made even more difficult when these individuals require surgery. Over a 4-year period, 6 patients with inhibitors to factor VIII and I patient with inhibitors to factor IX underwent surgery or invasive procedures at our institution. A total of 26 procedures were performed, primarily using the bypassing agent FEIBA for bleeding control. Excellent hemostasis was obtained in all cases, adding to accumulating data indicating that FEIBA is safe and effective in hemophilia patients with inhibitors who require surgery.
引用
收藏
页码：216 / 221
页数：6
相关论文
共 33 条
[1]   INHIBITORS IN HEMOPHILIA PATIENTS - CURRENT STATUS AND MANAGEMENT [J].
ALEDORT, L .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) :208-217
[2]   Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VII inhibitor bypass activity [J].
Aledort, LM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) :1700-1708
[3]  
*BAXT HEALTHC CORP, 2001, FEIBA VH PACK INS
[4]   Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII [J].
Bui, JD ;
Despotis, GD ;
Trulock, EP ;
Patterson, GA ;
Goodnough, LT .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 124 (04) :852-854
[5]   Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors [J].
Carcao, MD ;
Connolly, BL ;
Chait, P ;
Stain, AM ;
Acebes, M ;
Massicotte, P ;
Blanchette, VS .
HAEMOPHILIA, 2003, 9 (05) :578-583
[6]   A retrospective postlicensure survey of FEIBA efficacy and safety [J].
DiMichele, D. ;
Negrier, C. .
HAEMOPHILIA, 2006, 12 (04) :352-362
[7]  
DiMichele DM, 2002, THROMB HAEMOSTASIS, V87, P52
[8]   Safety of factor VIII inhibitor bypass activity (FEIBA®):: 10-year compilation of thrombotic adverse events [J].
Ehrlich, HJ ;
Henzl, MJ ;
Gomperts, ED .
HAEMOPHILIA, 2002, 8 (02) :83-90
[9]   Consensus recommendations for use of central venous access devices in haemophilia [J].
Ewenstein, BM ;
Valentino, LA ;
Journeycake, JM ;
Tarantino, MD ;
Shapiro, AD ;
Blanchette, VS ;
Hoots, WK ;
Buchanan, GR ;
Manco-Johnson, MJ ;
Rivard, GE ;
Miller, KL ;
Geraghty, S ;
Maahs, JA ;
Stuart, R ;
Dunham, T ;
Navickis, RJ .
HAEMOPHILIA, 2004, 10 (05) :629-648
[10]  
Ghosh K, 2004, HAEMOPHILIA, V10, P58, DOI 10.1046/j.1351-8216.2003.00839.x
1234